Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jordan Henderson (NPI 1013200328)

Field	Value
Entity Type	Individual
Organization	Jordan Henderson
Address	8121 Rourk St
City	Myrtle Beach
State	SC
ZIP	29572
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 18, 2011

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider’s Medicare activity is concentrated in high-cost oncology infusions: J9271, J9299, and J0897 together account for 67.1% of total Medicare revenue, and J9271 alone represents 38.1% of Medicare revenue. The mix (pembrolizumab and nivolumab as top revenue drivers, plus chemotherapy administration codes such as 96413 and 96417) is consistent with an infusion-based hematology/oncology practice that delivers immune checkpoint inhibitors and parenteral oncologic therapies.

Revenue scale is modest but Medicare‑focused: lifetime Medicare revenue is $3.1M while there is no Medicaid billing on file, so the provider is effectively single‑payer (Medicare) in the available claims dataset. This payer concentration means their commercial and Medicaid exposure is either minimal or not present in the billing records provided.

The provider’s tenure is established: NPI was enumerated on 2011-05-18 (~15 years ago), indicating about a decade and a half of formal enrollment in Medicare and time to build an infusion‑centric practice and referral relationships. Longevity supports the observed service mix (ongoing chemo/immunotherapy and chronic supportive care).

Competitive standing by code is mixed. For high-revenue immunotherapy codes the provider reports solid but not dominant national positions (J9271 ranks #202 of 1841, 89th percentile, labelled “typical, unremarkable volume”; J9299 ranks #101 of 505, 80th percentile, “typical, unremarkable volume”), whereas some infusion and supportive therapy codes show above‑typical volume (J1437 ranks #25 of 581, 96th percentile, “notably above typical national volume”; 96413 and 96417 also sit at higher percentiles and are described as “notably above typical national volume”).

Operationally the code mix signals a full-service oncology infusion operation with ancillary diagnostics and supportive care: significant billing for infusion drugs (J9271, J9299, J9305), chemotherapy administration (96413, 96417), supportive agents (J0897, J0885, J1569), and imaging (78815, A9552). The presence of PET/CT revenue (78815: $106.3K) and FDG dosing (A9552: $33.8K) indicates involvement in staging/monitoring workflows that commonly accompany active oncologic treatment.

There is notable concentration risk around a few drugs and services: the top three Medicare codes drive 67.1% of Medicare revenue, which exposes the provider’s topline to utilization or reimbursement shifts affecting pembrolizumab, nivolumab, and denosumab. Analysts tracking contract negotiations or specialty drug reimbursement changes should consider the outsized impact of these agents on the practice’s Medicare revenue.

E&M billing is unusually high relative to peers for office visits: 99214 is an “extreme outlier” (ranks #4102 of 479,517, 99th percentile) and 99213/99215 also sit at very high national percentiles. This pattern suggests a heavy outpatient management component — frequent, higher‑complexity follow‑up visits commonly associated with active systemic therapy management, toxicity monitoring, and care coordination.

Several specific codes point to differentiated service lines within the practice: high percentile ranks for J1437 (96th, notably above typical) and 96417 (95th, notably above typical) suggest above‑average volumes in iron infusion and multi‑agent infusion sessions respectively, positioning the provider as a regional center for both oncology infusions and certain non-oncologic infusible therapies. These areas could be leverage points in payer negotiations or partnership discussions.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

81 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	26,030	$40	$1.1M
J9299	Injection, nivolumab, 1 mg	25,540	$20	$613K
J0897	Injection, denosumab, 1 mg	13,320	$20	$239.8K
J1437	Injection, ferric derisomaltose, 10 mg	10,700	$20	$181.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,440	$90	$132.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	150	$700	$106.3K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	11,510	$10	$69.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	680	$90	$63.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,620	$40	$58.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	840	$60	$51.1K

Showing 1–10 of 81

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 81 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Jordan Henderson — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

81 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	7	30	19,700	$40	$832K
J9299	3	10	15,760	$20	$432K
J1569	18	20	3,860	$40	$161.4K
J1437	4	10	6,240	$20	$107.6K
J0897	26	250	2,400	$20	$91.2K
J3490	8	50	70	$510	$57.7K
J9305	1	10	4,130	$10	$46.8K
78815	32	120	80	$220	$25.8K
99214	123	7,860	160	$80	$23.2K
96413	7	150	140	$90	$22.1K

Showing 1–10 of 81

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jordan Henderson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dejuania Brown-rawls	SC	Hematology & Oncology Physician	$2.8M	$0
Patrick Francke	SC	Radiation Oncology Physician	$2.8M	$0
David Zaenger	SC	Radiation Oncology Physician	$2.3M	$0
Renwick Goldberg	SC	Hematology & Oncology Physician	$2.2M	$0
Stephen Andrews	SC	Radiation Oncology Physician	$2M	$0
Nikhil Patel	SC	Hematology & Oncology Physician	$1.9M	$0
Emily Touloukian	SC	Hematology & Oncology Physician	$1.5M	$0
Vijay Paudel	SC	Hematology & Oncology Physician	$912.8K	$0
Tanya Bralley	SC	Medical Physician Assistant	$208.3K	$0
Angela Brinegar	SC	Adult Health Nurse Practitioner	$152.6K	$0

Nearby Providers

Other providers in the same ZIP code as Jordan Henderson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Acs Primary Care Physicians - Southeast PC	SC	Emergency Medicine Physician	$0	$81.7M
Grand Strand Pediatrics & Adolescent Medicine, P.A.	SC	Pediatric Adolescent Medicine Physician	$0	$28M
Grand Strand Regional Medical Center LLC	SC	General Acute Care Hospital	$0	$27.4M
Carolina Regional Surgery Center. Ltd	SC	Ambulatory Surgical Clinic/Center	$3M	$1.7M
Coastal Carolina Primary Care, LLC	SC	Endocrinology, Diabetes & Metabolism Physician	$0	$4M
Brandon Coakley	SC	MOHS-Micrographic Surgery Physician	$3.5M	$0
Parkway Surgery Center	SC	Ambulatory Surgical Clinic/Center	$3.5M	$0
David Lazar	SC	Rheumatology Physician	$2.7M	$0
Stephen Hammond	SC	Dermatopathology Physician	$2.3M	$0
David Chetrit	SC	Rheumatology Physician	$2.3M	$0

Jordan Henderson — Billing Profile & Reimbursement Data

Sign up for Jordan Henderson — Billing Profile & Reimbursement Data policy alerts

Jordan Henderson — Billing Profile & Reimbursement Data

Sign up for Jordan Henderson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References